{"id":1894,"date":"2017-02-17T11:09:33","date_gmt":"2017-02-17T11:09:33","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1894"},"modified":"2025-05-19T10:49:30","modified_gmt":"2025-05-19T05:19:30","slug":"trail-receptor-agonists-emerging-target-therapies-against-cancer","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/trail-receptor-agonists-emerging-target-therapies-against-cancer","title":{"rendered":"TRAIL Receptor Agonists: Emerging target therapies against Cancer"},"content":{"rendered":"

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand (Apo2L) is a type II trans membrane protein belonging to the Tumor Necrosis Factor (TNF) superfamily that are widely expressed on the surface of Natural Killer (NK) and T cells<\/a>, macrophages<\/a> and dendrite cells.<\/p>\n

These proteins bind to the Death receptor 4 (DR4) and 5 (DR5), and trigger apoptosis in tumor cells. Discovery of TRAIL proteins and its receptors came as a promising therapeutic approach in anti-cancer target therapies because of its unique quality of binding to variety of tumor cells while sparing the normal vital cells of the body. Unfortunately, first generation of TRAIL agonist didn\u2019t match the expected clinical efficacy as most tumors were resistant to the apoptosis induced by TRAIL proteins. Later, it was identified that poor clinical efficacy of these agents was due to their insufficient agonist activity.<\/p>\n

Since then, vigorous research is going on for developing novel TRAIL-Receptor targeting agents with increased agonistic activity. Currently, many second generation therapies targeting TRAIL receptor are in development. For instance, hvTRA, a novel second generation TRAIL agonist has demonstrated an efficient and sustained reduction in melanoma cell growth in cell lines and xenograft models. Recently, a research demonstrated that TRAIL-coated lipid-nanoparticles improves TRAIL cytotoxic ability. Combination of TRAIL agonist along with other anti-cancer drugs has the potential to overcome resistance and can provide greater anti-tumor activity. For example, Choline kinase inhibitors in combination with TRAIL enhances the TRAIL-induced apoptosis and can overcome the resistance.<\/p>\n

Although, the combination approach and second generation TRAIL agonist are mostly in early clinical developmental stage, but evidences based on various research work indicates the emergence of promising TRAIL agonist in near future. Companies like Apogenix, Genmab, MedImmune etc., are developing drug candidates which are likely to enter into clinical studies in next few years.<\/p>\n

Insight by:
\n<\/em>Jyoti Kumari
\n<\/em>Associate Analyst
\n<\/em><\/p>\n

DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business, facilitating their decision-making. DelveInsight also serves as a knowledge partner for business strategy and market research. We provide comprehensive analytical reports across various therapeutic\u00a0indications. DelveInsight has a database of 3000+ high-quality analytical reports<\/a>.<\/h6>\n","protected":false},"excerpt":{"rendered":"

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand (Apo2L) is a type II trans membrane protein belonging to the Tumor Necrosis Factor (TNF) superfamily that are widely expressed on the surface of Natural Killer (NK) and T cells, macrophages and dendrite cells. These proteins bind to the Death receptor 4 (DR4) […]<\/p>\n","protected":false},"author":1,"featured_media":1900,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[1429,167,735,634,17453,393,782,781],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-1894","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-apogenix","tag-clinical-research","tag-clinical-studies","tag-drug-development","tag-genmab","tag-medimmune","tag-trail-agonist","tag-trail-receptor","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nTRAIL Receptor Agonists: A novel therapeutics option against Cancer<\/title>\n<meta name=\"description\" content=\"Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand (Apo2L) is a type II trans membrane protein belonging\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/trail-receptor-agonists-emerging-target-therapies-against-cancer\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TRAIL Receptor Agonists: A novel therapeutics option against Cancer\" \/>\n<meta property=\"og:description\" content=\"Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand (Apo2L) is a type II trans membrane protein belonging\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/trail-receptor-agonists-emerging-target-therapies-against-cancer\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-02-17T11:09:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-19T05:19:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021627\/1-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"329\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TRAIL Receptor Agonists: A novel therapeutics option against Cancer","description":"Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand (Apo2L) is a type II trans membrane protein belonging","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/trail-receptor-agonists-emerging-target-therapies-against-cancer","og_locale":"en_US","og_type":"article","og_title":"TRAIL Receptor Agonists: A novel therapeutics option against Cancer","og_description":"Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand (Apo2L) is a type II trans membrane protein belonging","og_url":"https:\/\/www.delveinsight.com\/blog\/trail-receptor-agonists-emerging-target-therapies-against-cancer","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-02-17T11:09:33+00:00","article_modified_time":"2025-05-19T05:19:30+00:00","og_image":[{"width":400,"height":329,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021627\/1-1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/trail-receptor-agonists-emerging-target-therapies-against-cancer","url":"https:\/\/www.delveinsight.com\/blog\/trail-receptor-agonists-emerging-target-therapies-against-cancer","name":"TRAIL Receptor Agonists: A novel therapeutics option against Cancer","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/trail-receptor-agonists-emerging-target-therapies-against-cancer#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/trail-receptor-agonists-emerging-target-therapies-against-cancer#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021627\/1-1.jpg","datePublished":"2017-02-17T11:09:33+00:00","dateModified":"2025-05-19T05:19:30+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand (Apo2L) is a type II trans membrane protein belonging","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/trail-receptor-agonists-emerging-target-therapies-against-cancer"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/trail-receptor-agonists-emerging-target-therapies-against-cancer#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021627\/1-1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021627\/1-1.jpg","width":400,"height":329,"caption":"TRAIL-Receptor-Agonists"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021627\/1-1-300x247.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Apogenix<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">clinical research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Clinical Studies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">drug development<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Genmab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Medimmune<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">TRAIL Agonist<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">TRAIL Receptor<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Apogenix<\/span>","<span class=\"advgb-post-tax-term\">clinical research<\/span>","<span class=\"advgb-post-tax-term\">Clinical Studies<\/span>","<span class=\"advgb-post-tax-term\">drug development<\/span>","<span class=\"advgb-post-tax-term\">Genmab<\/span>","<span class=\"advgb-post-tax-term\">Medimmune<\/span>","<span class=\"advgb-post-tax-term\">TRAIL Agonist<\/span>","<span class=\"advgb-post-tax-term\">TRAIL Receptor<\/span>"]}},"comment_count":"1","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Feb 17, 2017","modified":"Updated on May 19, 2025"},"absolute_dates_time":{"created":"Posted on Feb 17, 2017 11:09 am","modified":"Updated on May 19, 2025 10:49 am"},"featured_img_caption":"TRAIL-Receptor-Agonists","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1894"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1894\/revisions"}],"predecessor-version":[{"id":32212,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1894\/revisions\/32212"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1900"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1894"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1894"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}